D. E. Shaw & Co. Inc. Reduces Stock Position in Altimmune, Inc. (NASDAQ:ALT)

D. E. Shaw & Co. Inc. trimmed its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 39.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 459,833 shares of the company's stock after selling 298,171 shares during the period. D. E. Shaw & Co. Inc. owned 0.65% of Altimmune worth $3,315,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Wells Fargo & Company MN raised its holdings in shares of Altimmune by 69.3% in the 4th quarter. Wells Fargo & Company MN now owns 215,538 shares of the company's stock worth $1,554,000 after purchasing an additional 88,209 shares during the period. SBI Securities Co. Ltd. purchased a new position in shares of Altimmune in the 4th quarter worth about $45,000. Marshall Wace LLP purchased a new position in shares of Altimmune in the 4th quarter worth about $472,000. Bellevue Group AG raised its holdings in shares of Altimmune by 9.5% in the 4th quarter. Bellevue Group AG now owns 945,446 shares of the company's stock worth $6,817,000 after purchasing an additional 81,786 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Altimmune by 5.7% in the 4th quarter. Northern Trust Corp now owns 665,916 shares of the company's stock worth $4,801,000 after purchasing an additional 35,918 shares during the period. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Stock Performance

Shares of NASDAQ:ALT traded down $0.06 during mid-day trading on Friday, hitting $5.71. 1,651,677 shares of the company traded hands, compared to its average volume of 2,818,663. The firm has a market cap of $463.12 million, a P/E ratio of -3.68 and a beta of 1.13. Altimmune, Inc. has a 52-week low of $3.55 and a 52-week high of $11.16. The firm's 50 day simple moving average is $5.11 and its 200 day simple moving average is $6.52.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.09. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period last year, the business posted ($0.34) EPS. Equities research analysts expect that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Insider Activity at Altimmune

In other Altimmune news, CFO Gregory L. Weaver acquired 10,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were bought at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now directly owns 10,000 shares of the company's stock, valued at $52,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 4.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ALT. Wall Street Zen upgraded Altimmune from a "sell" rating to a "hold" rating in a report on Thursday. William Blair restated a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. Finally, HC Wainwright restated a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a report on Thursday, April 3rd. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Altimmune has a consensus rating of "Moderate Buy" and a consensus price target of $20.20.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.